|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1201 Maryland Avenue SW |
Address2 | Suite 900 |
City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 6245-12
|
||||||||
|
6. House ID# 325050000
|
TYPE OF REPORT | 8. Year | 2013 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Brent DelMonte, Vice President for Federal Government Relations |
Date | 04/22/2013 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
USDA/APHIS Agricultural Biotechnology Regulations
Efficient Science-Based Reviews of Biotech Products
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
EPA Regulations on Agricultural Biotechnology
Genetically Engineered (GE) Animals
FDA Approval
Amendment to Restrict FDA Approval of GE Salmon
Labeling
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2014
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
S. 622: Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013
S. Con. Res. 8: Senate Budget Resolution
Export Registrations for Products with Expired Patents
Labeling of Genetically Engineered Crops
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2014
Adventitious Presence (Low Level Presence)
U.S. Low Level Presence Policy
S. 10: Agriculture Reform, Food, and Jobs Act of 2013 S (Farm Bill)
Foreign Agricultural Biotechnology Laws and Regulations
Asynchrony of International Approvals
China Biotechnology Regulations
International Biotechnology Agreement
EU Biotechnology Bilateral Discussions
Low-Level Presence Foreign Government Policies
Agricultural Biotechnology Regulatory Reform and Modernization
S. 10: Agriculture Reform, Food, and Jobs Act of 2013 (Farm Bill)
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
Benefits of Ag-Biotech Research and Innovation
Regulatory Review of Animal Pharmaceuticals
S. 622: Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013
TransPacific Partnership
Sanitary and Phytosanitary Issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Agriculture - Dept of (USDA), U.S. Trade Representative (USTR), White House Office,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cathleen |
Enright |
|
|
|
David |
Edwards |
|
|
|
Tracey |
LaTurner |
|
|
|
Dana |
O'Brien |
|
|
|
Matthew |
O'Mara |
|
|
|
Brent |
Del Monte |
|
|
|
Derrick |
White |
|
|
|
Anna. |
Weinstein |
|
|
|
Tom |
DiLenge |
|
|
|
Matthew |
Schumaker |
|
|
|
Joseph |
Damond |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
Genetically Engineered (GE) Animals
Labeling
FDA Approval
Amendment to Restrict FDA Approval of GE Salmon
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2014
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
S. 622: Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013
S. Con. Res. 8: Senate Budget Resolution
Regulatory Review of Animal Pharmaceuticals
S. 622: Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), U.S. Trade Representative (USTR), Office of Science & Technology Policy (OSTP), White House Office, Agriculture - Dept of (USDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cathleen |
Enright |
|
|
|
David |
Edwards |
|
|
|
Dana |
O'Brien |
|
|
|
Derrick |
White |
|
|
|
Brent |
Del Monte |
|
|
|
Anna |
Weinstein |
|
|
|
Tracey |
LaTurner |
|
|
|
Matthew |
Schumaker |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Sequestration of PDUFA Fees
Implementation of S. 365: Budget Control Act
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development, and Procurement
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2014
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
H.R. 307: Pandemic and All-Hazards Preparedness Reauthorization Act
Funding for FDA (Human Drug Review, Biologics, Food Safety, Critical Path, Reagan-Udall Foundation, Medical Countermeasures, Center for Veterinary Medicine, Scientific Infrastructure)
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2014
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
Funding for Renewable Chemicals/Bio-based Products
Expansion of Biorefinery Assistance Program to Renewable Chemicals and Bio-based Products
Reauthorization/Funding of USDA Bio-Preferred Program
S.10: Agriculture Reform, Food, and Jobs Act of 2013 (Farm Bill)
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
Funding for Biofuels
Department of Defense Funding/Application of Advanced Biofuels
Department of Defense Appropriations Act for FY 2014
Department of Energy and Water and Related Agencies Appropriations Act for FY 2014
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013 (Toomey Amendment)
Funding for Centers for Disease Control and Prevention Vaccine Programs
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2014
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
Funding for National Institutes of Health
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2014
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
Cures Acceleration Network
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2014
Funding for Biomass Programs
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
Reauthorization/Funding of Biomass Crop Assistance Program
Reauthorization/Funding of Biomass R&D Program
S. 10: Agriculture Reform, Food, and Jobs Act of 2013 (Farm Bill)
Reimbursement for Innovative Products
Medicare Part D Prescription Drug Program
Medicare Part B Physician-Administered Products
H.Con.Res. 25: House Budget Resolution (Democratic Caucus Substitute)
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
Funding for Biorefineries
Reauthorization/Funding of Biorefinery Assistance Program
DOE Biomass Program
Department of Defense Funding
S. 10: Agriculture Reform, Food, and Jobs Act of 2013 (Farm Bill)
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013 (Toomey Amendment)
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
S. Con. Res. 8: Senate Budget Resolution
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office, Office of Management & Budget (OMB), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tracey |
LaTurner |
|
|
|
Matt |
Carr |
|
|
|
Cathleen |
Enright |
|
|
|
Andrew |
Emmett |
|
|
|
Cartier |
Esham |
|
|
|
Brent |
DelMonte |
|
|
|
Dana |
O'Brien |
|
|
|
Sara |
Radcliffe |
|
|
|
Jeanne |
Haggerty |
|
|
|
David |
Edwards |
|
|
|
Kelly |
Cappio |
|
|
|
Phyllis |
Arthur |
|
|
|
Rina |
Singh |
|
|
|
Derrick |
White |
|
|
|
Sandra |
Dennis |
|
|
|
Catharine |
Harris |
|
|
|
Anna |
Weinstein |
|
|
|
Charles |
Fritts |
|
|
|
Matthew |
Schumaker |
|
|
|
Erick |
Lutt |
|
Legislative Assistant |
|
Erick |
Lutt Cont. |
|
Sen. Ben Nelson, 4-8-2009 to 1-3-2013 |
|
Erick |
Lutt |
|
Deputy Legislative Assistant |
|
Erick |
Lutt Cont. |
|
Sen. Ben Nelson, 3-25-2006 to 4-7-2009 |
|
Erick |
Lutt |
|
Staff Assistant |
|
Erick |
Lutt Cont. |
|
Sen. Ben Nelson, 3-25-2005 to 3-24-2006 |
|
. |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CAW
16. Specific lobbying issues
Climate Change Benefits of Biofuels
Department of Defense Applications of Advanced Biofuels
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
O'Brien |
|
|
|
Matt |
Carr |
|
|
|
Brent |
Del Monte |
|
|
|
Erick |
Lutt |
|
Legislative Assistant |
|
Erick |
Lutt Cont. |
|
Sen. Ben Nelson, 4-8-2009 to 1-3-2013 |
|
Erick |
Lutt |
|
Deputy Legislative Assistant |
|
Erick |
Lutt Cont. |
|
Sen. Ben Nelson, 3-25-2006 to 4-7-2009 |
|
Erick |
Lutt |
|
Staff Assistant |
|
Erick |
Lutt Cont. |
|
Sen. Ben Nelson, 3-25-2005 to 3-24-2006 |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Patent Reform
Litigation
TransPacific Partnership
Data and Intellectual Property Protection for Pharmaceuitcalsl
World Trade Organization Special 301 Submissions
Generic Drug Patent Settlements
S. Con. Res. 8: Senate Budget Resolution
Genetic Resource Patent Disclosure Requirement
World Intellectual Property Organization
DNA Patenting and Licensing
Intellectual Property International Enforcement
Compulsory Licensing
International Patent Law Harmonization
Patent Exhaustion
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR), Patent & Trademark Office (PTO)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lila |
Feisee |
|
|
|
Hans |
Sauer |
|
|
|
Cathleen |
Enright |
|
|
|
Brent |
Del Monte |
|
|
|
Tom |
DiLenge |
|
|
|
Joseph |
Damond |
|
|
|
Roy |
Zwahlen |
|
|
|
Anna |
Weinstein |
|
|
|
Derrick |
White |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
Livestock Cloning/Project Labeling
Discussions with EU on Animal Cloning
USDA/APHIS Agricultural Biotechnology Regulations
Efficient Science-Based Reviews of Biotech Products
Genetically Engineered (GE) Animals
FDA Approval
Labeling
Amendment to Restrict FDA Approval of GE Salmon
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2014
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
S. 622: Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013
S. Con. Res. 8: Senate Budget Resolution
Generic Drug Patent Settlements
S. Con. Res. 8: Senate Budget Resolution
Labeling of Genetically Engineered Crops
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2014
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
Drug Safety and Review
Implementation of S. 3187: The Food and Drug Administration Safety and Innovation Act
Regulatory Reforms for Innovative Products
Expedited Approval Pathways
E-Pedigree and Anti-Counterfeiting
Supply Chain Integrity
Pharmacy Compounding
Funding for FDA (Human Drug Review, Biologics, Food Safety, Critical Path, Reagan-Udall Foundation, Medical Countermeasures, Center for Veterinary Medicine, Scientific Infrastructure)
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2014
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), Office of Science & Technology Policy (OSTP), U.S. Trade Representative (USTR), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cathleen |
Enright |
|
|
|
David |
Edwards |
|
|
|
Andrew |
Emmett |
|
|
|
Anna |
Weinstein |
|
|
|
Sara |
Radcliffe |
|
|
|
Sandra |
Dennis |
|
|
|
Derrick |
White |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Matthew |
Schumaker |
|
|
|
Brent |
DelMonte |
|
|
|
Cartier |
Esham |
|
|
|
Tom |
DiLenge |
|
|
|
Jeanne |
Haggerty |
|
|
|
Alan |
Eisenberg |
|
|
|
. |
. |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
Biofuels
Production Tax Credit Extension
Accelerated Depreciation Extension
Department of Defense Funding/Application of Advanced Biofuels
Biofuels Cont.
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013 (Toomey Amendment)
Renewable Fuel Standard
Department of Defense Appropriations Act for FY 2014
Energy and Water Development and Related Agencies Appropriations Act for FY 2014
Biorefineries
Reauthorization/Funding of Biorefinery Assistance Program
DOE Biomass Program
Department of Defense Funding
S. 10: Agriculture Reform, Food, and Jobs Act of 2013 (Farm Bill)
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013 (Toomey Amendment)
S. Con. Res. 8: Senate Budget Resolution
Renewable Chemicals/Bio-based Products
New Production Tax Credit for Renewable Chemicals
Expansion of Advanced Manufacturing Investment Tax Credit to Renewable Chemicals and Bio-Based Products
Expansion of Master Limited Partnerships to Renewable Chemicals
Expansion of Biorefinery Assistance Program to Renewable Chemicals and Bio-based Products
Reauthorization/Funding of USDA Bio-Preferred Program
S. 10: Agriculture Reform, Food, and Jobs Act of 2013 (Farm Bill)
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
Biomass Programs
Reauthorization/Funding of Biomass Crop Assistance Program
Reauthorization/Funding of Biomass R&D Program
S. 10: Agriculture Reform, Food, and Jobs Act of 2013 (Farm Bill)
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Environmental Protection Agency (EPA),
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matt |
Carr |
|
|
|
Dana |
O'Brien |
|
jjhjhjhjhjhjhjhjhjhhjhjjhjhhjjhjhhjjhhjjhjhjhhjhjjhjhjj |
|
Tracey |
LaTurner |
|
|
|
Charles |
Fritts |
|
|
|
Rina |
Singh |
|
|
|
Brent |
Del Monte |
|
|
|
Erick |
Lutt |
|
Legislative Assistant |
|
Erick |
Lutt Cont. |
|
Sen. Ben Nelson, 4-8-2009 to 1-3-2013 |
|
Erick |
Lutt |
|
Deputy Legislative Assistant |
|
Erick |
Lutt Cont. |
|
Sen. Ben Nelson, 3-25-2006 to 4-7-2009 |
|
Erick |
Lutt |
|
Staff Assistant |
|
Erick |
Lutt Cont. |
|
Sen. Ben Nelson, 3-25-2005 to 3-24-2006 |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Livestock Cloning/Project Labeling
Discussions with EU on Animal Cloning
Genetically Engineered (GE) Animals
FDA Approval
Labeling
Amendment to Restrict FDA Approval of GE Salmon
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2014
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
S. 622: Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013
S. Con. Res. 8: Senate Budget Resolution
Labeling of Genetically Engineered Crops
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2014
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Office of Science & Technology Policy (OSTP), Agriculture - Dept of (USDA), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cathleen |
Enright |
|
|
|
David |
Edwards |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
Del Monte |
|
|
|
Derrick |
White |
|
|
|
Anna |
Weinstein |
|
|
|
Matthew |
Schumaker |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FUE
16. Specific lobbying issues
Biofuels
Production Tax Credit Extension
Accelerated Depreciation Extension
Department of Defense Funding/Application of Advanced Biofuels
Biofuels Cont.
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013 (Toomey Amendment)
Renewable Fuel Standard
Department of Defense Appropriations Act for FY 2014
Energy and Water Development and Related Agencies Appropriations Act for FY 2014
Biorefineries
Reauthorization/Funding of Biorefinery Assistance Program
DOE Biomass Program
Department of Defense Funding
S. 10: Agriculture Reform, Food, and Jobs Act of 2013 (Farm Bill)
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013 (Toomey Amendment)
S. Con. Res. 8: Senate Budget Resolution
Renewable Chemicals/Bio-based Products
New Production Tax Credit for Renewable Chemicals
Expansion of Advanced Manufacturing Investment Tax Credit to Renewable Chemicals and Bio-Based Products Expansion of Master Limited Partnerships to Renewable Chemicals
Expansion of Biorefinery Assistance Program to Renewable Chemicals and Bio-based Products
Reauthorization/Funding of USDA Bio-Preferred Program
S. 10: Agriculture Reform, Food, and Jobs Act of 2013 (Farm Bill)
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
Biomass Programs
Reauthorization/Funding of Biomass Crop Assistance Program
Reauthorization/Funding of Biomass R&D Program
S. 10: Agriculture Reform, Food, and Jobs Act of 2013 (Farm Bill)
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Environmental Protection Agency (EPA),
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matt |
Carr |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Charles |
Fritts |
|
|
|
Rina |
Singh |
|
|
|
Brent |
DelMonte |
|
|
|
Erick |
Lutt |
|
Legislative Assistant |
|
Erick |
Lutt Cont. |
|
Sen. Ben Nelson, 4-8-2009 to 1-3-2013 |
|
Erick |
Lutt |
|
Deputy Legislative Assistant |
|
Erick |
Lutt Cont. |
|
Sen. Ben Nelson, 3-25-2006 to 4-7-2009 |
|
Erick |
Lutt |
|
Staff Assistant |
|
Erick |
Lutt Cont. |
|
Sen. Ben Nelson, 3-25-2005 to 3-24-2006 |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Funding for National Institutes of Health
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2014
Funding for Centers for Disease Control and Prevention Vaccine Programs
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2014
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
Vaccine Access/Financing
Tax for Seasonal Influenza Funding
H.R. 425/S. 391: A bill to amend the Internal Revenue Code of 1986 to include vaccines against seasonal influenza
within the definition of taxable vaccines
Adult Immunization Policies
Adult Immunization Senate Discussion Draft
340B Drug Pricing Program
HRSA Implementation of Program Changes
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Drug Safety and Review
Implementation of S. 3187: The Food and Drug Administration Safety and Innovation Act
Regulatory Reforms for Innovative Products
Expedited Approval Pathways
E-Pedigree and Anti-Counterfeiting
Supply Chain Integrity
Pharmacy Compounding
Funding for FDA (Human Drug Review, Biologics, Food Safety, Critical Path, Reagan-Udall Foundation, Medical Countermeasures, Center for Veterinary Medicine, Scientific Infrastructure)
Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2014
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
Independent Payment Advisory Board
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development, and Procurement
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2014
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
H.R. 307: Pandemic and All-Hazards Preparedness Reauthorization Act
Cures Acceleration Network
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2014
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Biodefense Research, Development, and Procurement (Non-Funding Issues)
H.R. 307: Pandemic and All-Hazards Preparedness Reauthorization Act
Reimbursement for Innovative Products
Medicare Part D Prescription Drug Program
Medicare Part B Physician-Administered Products
H.Con.Res. 25: House Budget Resolution (Democratic Caucus Substitute)
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
U.S./European Union High-Level Dialogue on Regulatory Issues
Sequestration of PDUFA Fees
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
Implementation of S. 365: Budget Control Act
TransPacific Partnership
Data and Intellectual Property Protection for Pharmaceuitcalsl
Regulatory Transparency
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Natl Institutes of Health (NIH), U.S. Trade Representative (USTR), Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Catharine |
Harris |
|
|
|
Alan |
Einsenberg |
|
|
|
Sandra |
Dennis |
|
|
|
Andrew |
Emmett |
|
|
|
Matthew |
Schumaker |
|
|
|
Jeanne |
Haggerty |
|
|
|
Sara |
Radcliffe |
|
|
|
Phyllis |
Arthur |
|
|
|
Anna |
Weinstein |
|
|
|
Derrick |
White |
|
|
|
Cartier |
Esham |
|
|
|
Charles |
Fritts |
|
|
|
Tom |
DiLenge |
|
|
|
Tracey |
LaTurner |
|
|
|
Laurel |
Todd |
|
|
|
Brent |
Del Monte |
|
|
|
Alyson |
Pusey |
|
|
|
Kelly |
Cappio |
|
|
|
Joseph |
Damond |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
H.R. 307: Pandemic and All-Hazards Preparedness Reauthorization Act
Biodefense Research, Development, and Procurement (Non-Funding Issues)
H.R. 307: Pandemic and All-Hazards Preparedness Reauthorization Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Derrick |
White |
|
|
|
Anna |
Weinstein |
|
|
|
Phyllis |
Arthur |
|
|
|
Tracey |
LaTurner |
|
|
|
Jeanne |
Haggerty |
|
|
|
Brent |
Del Monte |
|
|
|
Sara |
Radcliffe |
|
|
|
Kelly |
Cappio |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Funding for National Institutes of Health
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2014
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2014
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
H.R. 307: Pandemic and All-Hazards Preparedness Reauthorization Act
Cures Acceleration Network
Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2014
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Biodefense Research, Development, and Procurement (Non-Funding Issues)
H.R. 307: Pandemic and All-Hazards Preparedness Reauthorization Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS),
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sara |
Radcliffe |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tracey |
LaTurner |
|
|
|
Anna |
Weinstein |
|
|
|
Phyllis |
Arthur |
|
|
|
Cartier |
Esham |
|
|
|
Kelly |
Cappio |
|
|
|
Brent |
Del Monte |
|
|
|
Derrick |
White |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Reimbursement for Innovative Products
Medicare Part D Prescription Drug Program
Reimbursement for Innovative Products Cont.
Medicare Part B Physician-Administered Products
H.Con.Res. 25: House Budget Resolution (Democratic Caucus Substitute)
H.R. 933: Consolidated and Further Continuing Appropriations Act for FY 2013
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alyson |
Pusey |
|
|
|
Laurel |
Todd |
|
|
|
Matthew |
Schumaker |
|
|
|
Brent |
Del Monte |
|
|
|
Jeanne |
Haggerty |
|
|
|
Anna |
Weinstein |
|
|
|
Derrick |
White |
|
|
|
Sara |
Radcliffe |
|
|
|
Catharine |
Harris |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SCI
16. Specific lobbying issues
Small Business Innovation Research (SBIR) Program
Implementation of Final Rulemaking
Research & Development Tax Credit Extension
Startup Innovation Credit (Senator Coons Discussion Draft)
Innovative Research and Competitiveness Act (Senator Carper Discussion Draft)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cartier |
Esham |
|
|
|
Charles |
Fritts |
|
|
|
Brent |
Del Monte |
|
|
|
Alan |
Eisenberg |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Charles |
Crain |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Sarbanes Oxley Section 404 (b)
Mandatory Audit Firm Rotation (Rep. Hurt Discussion Draft)
Tax Reform
Capital Formation Investment Incentives
High Technology Small Business Research Incentives Act (Discussion Draft)
Expansion of Exemption Under SEC Regulation A
H.R. 701: To amend a provision of the Securities Act of 1933 directing the Securities and Exchange Commission to
add a particular class of securities to those exempted under such Act to provide a eadline for such action
Legislative Amendments to SEC Rule 12b-2 Filing Status Definitions
Small Business Innovation Research (SBIR) Program
Implementation of Final Rulemaking
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Treasury - Dept of, Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cartier |
Esham |
|
|
|
Charles |
Fritts |
|
|
|
Alan |
Eisenberg |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Charles |
Crain |
|
|
|
Brent |
Del Monte |
|
|
|
Matthew |
Schumaker |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Biofuels
Production Tax Credit Extension
Accelerated Depreciation Extension
Research & Development Tax Credit Extension
Startup Innovation Credit (Senator Coons Discussion Draft)
Innovative Research and Competitiveness Act (Senator Carper Discussion Draft)
Capital Formation Investment Incentives
High Technology Small Business Research Incentives Act (Discussion Draft)
Vaccine Access/Financing
Tax for Seasonal Influenza Funding
H.R. 425/S.391: A bill to amend the Internal Revenue Code of 1986 to include vaccines against seasonal influenza
within the definition of taxable vaccines
Tax Reform
Renewable Chemicals/Bio-based Products
New Production Tax Credit for Renewable Chemicals
Expansion of Advanced Manufacturing Investment Tax Credit to Renewable Chemicals and Bio-Based Products
Expansion of Master Limited Partnerships to Renewable Chemicals
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Treasury - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matt |
Carr |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Anna |
Weinstein |
|
|
|
Tracey |
LaTurner |
|
|
|
Rina |
Singh |
|
|
|
Charles |
Fritts |
|
|
|
Kelly |
Cappio |
|
|
|
Phyllis |
Arthur |
|
|
|
Alan |
Einsenberg |
|
|
|
Derrick |
White |
|
|
|
Brent |
Del Monte |
|
|
|
Dana |
O'Brien |
|
|
|
Erick |
Lutt |
|
Legislative Assistant |
|
Erick |
Lutt Cont. |
|
Sen. Ben Nelson, 4-8-2009 to 1-3-2013 |
|
Erick |
Lutt |
|
Deputy Legislative Assistant |
|
Erick |
Lutt Cont. |
|
Sen Ben Nelson, 3-25-2006 to 4-7-2009 |
|
Erick |
Lutt |
|
Staff Assistant |
|
Erick |
Lutt Cont. |
|
Sen Ben Nelson, 3-25-2005 to 3-24-2006 |
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
World Trade Organization Special 301 Submissions
Export Registrations for Products with Expired Patents
Intellectual Property International Enforcement
Compulsory Licensing
Foreign Agricultural Biotechnology Laws and Regulations
China Biotechnology Regulations
Low-Level Presence Foreign Government Policies
International Biotechnology Agreement
Asynchrony of International Approvals
EU Biotechnology Bilateral Discussions
TransPacific Partnership
Data and Intellectual Property Protection for Pharmaceuitcalsl
Regulatory Transparency
Sanitary and Phytosanitary Issues
U.S./European Union High-Level Dialogue on Regulatory Issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR), Agriculture - Dept of (USDA), Patent & Trademark Office (PTO), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
DiLenge |
|
|
|
Matthew |
Schumaker |
|
|
|
Dana |
O'Brien |
|
|
|
Lila |
Feisee |
|
|
|
Hans |
Sauer |
|
|
|
Jeanne |
Haggerty |
|
|
|
Roy |
Zwahlen |
|
|
|
Matthew |
O'Mara |
|
|
|
Cathleen |
Enright |
|
|
|
Brent |
Del Monte |
|
|
|
Joseph |
Damond |
|
|
|
Anna |
Weinstein |
|
|
|
. |
. |
|
|
|
. |
. |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
PHA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address: BIO maintains a list of all of its members on its website at http://bio.org/membership/index.asp
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |